Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02406729|
Recruitment Status : Active, not recruiting
First Posted : April 2, 2015
Last Update Posted : January 18, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is a randomized, multicenter, double-blind, placebo-controlled Phase III study that will evaluate efficacy and safety of a live attenuated, tetravalent, lyophilized dengue vaccine produced by Butantan Institute.
The study will be carried out in multiple sites in Brazil. The study will be community-based in select urban areas where there's dengue transmission.
Study's intervention will be a single dose of the tetravalent dengue vaccine or placebo in a ratio 2:1. For efficacy analysis will be considered all dengue cases occurring after 28 days post-vaccination in the entire population of 16944 participants.
For safety analysis participants will be divided in three age groups: 18 to 59 ys, 7-17 ys and 2 to 6 ys. In each of these age groups there will be a minimum of 4992 participants. The age groups of 18 to 59 ys and 7 to 17 ys will start first. Once safety data for the first 21 days after vaccination is analysed for 450 participants in 7-to17-ys age group, the following group, of 2 to 6 ys, will start.
The study's hypothesis is that the vaccine under investigation and produced by Butantan Institute is safe and provides protection against dengue symptomatic disease of 80% or more with a lower bound of the 95% confidence interval of 25%. This way, the expected number of dengue cases virologically confirmed is 24 or more which will provide a response in terms of vaccine efficacy.
All participants will be followed up for five years to verify dengue incidence, regardless severity.
|Condition or disease||Intervention/treatment||Phase|
|Dengue||Biological: Dengue 1,2,3,4 (attenuated) vaccine Other: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16935 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Immunogenicity of the Dengue 1, 2, 3, 4 (Attenuated) Vaccine From Instituto Butantan|
|Actual Study Start Date :||February 22, 2016|
|Actual Primary Completion Date :||July 13, 2021|
|Estimated Study Completion Date :||November 2024|
Experimental: Dengue 1,2,3,4 (attenuated) vaccine
Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
Biological: Dengue 1,2,3,4 (attenuated) vaccine
Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
Placebo Comparator: Placebo
Placebo Single dose, SC
- Efficacy (incidence density of symptomatic dengue cases, virologically confirmed) [ Time Frame: Five years post vaccination, all cases after 28 days post-vaccination ]The primary efficacy outcome is incidence density of symptomatic dengue cases, virologically confirmed, after 28 days post-vaccination. Virological confirmation might be done by viral isolation, RT-PCR and/or detection of NS1.
- Safety (adverse reactions) [ Time Frame: In the first 21 days post-vaccination ]The primary safety outcome is the frequency of local and systemic adverse reactions, solicited and non-solicited in the three age groups, within the first 21 days post-vaccination. Adverse reactions are defined as adverse events that have a reasonable causal relationship with vaccination.
- Efficacy (incidence density of dengue cases confirmed virologically, regarding previous exposure to dengue viruses. ) [ Time Frame: at five years post vaccination, all cases after 28 days post-vaccination ]The incidence density of dengue cases confirmed virologically after 28 days of vaccination, regarding previous exposure to dengue viruses. To demonstrate previous exposure or not to dengue viruses, validated serological methods such as: Elisa IgG Indirect, hemagglutination inhibition test or neutralizing antibodies (e.g., VRNT) or another validated test will be used. In case of doubtful results, more than one technique may be used to confirm the diagnosis.
- Efficacy (incidence density of dengue cases confirmed virologically, regarding the viral serotype) [ Time Frame: Five years post vaccination, all cases after 28 days post-vaccination ]The incidence density of dengue cases confirmed virologically after 28 days of vaccination, regarding the viral serotype. Virological diagnosis of the viral serotype will be performed using the viral isolation technique or RT-PCR.
- Efficacy (incidence density of cases of severe dengue and/or with alarm signs, including cases hospitalized or not) [ Time Frame: Five years post vaccination, all cases after 28 days post-vaccination ]Incidence density of cases of severe dengue and/or with alarm signs, including cases hospitalized or not, after 28 days of vaccination. Laboratory confirmation of these cases will occur through serological and/or virological tests.
- Safety ( frequency of solicited and unsolicited local and systemic adverse reactions in participants regarding previous exposure to dengue viruses ) [ Time Frame: In the first 21 days post-vaccination ]The frequency of solicited and unsolicited local and systemic adverse reactions in participants regarding previous exposure to dengue viruses during the 21-day period after vaccination.
- Safety (frequency of unsolicited adverse reactions) [ Time Frame: Five years post vaccination, all cases after the first 21 days post-vaccination ]The frequency of unsolicited adverse reactions after 21 days of vaccination until the end of the study.
- Immunogenicity (consistency of the immune response to different batches of the vaccine ) [ Time Frame: 4 weeks post vaccination ]The geometric mean of neutralizing antibody titers for each serotype in the fourth week after vaccination in a subgroup of adult participants without previous exposure to dengue immunized with three consecutive batches of dengue vaccine 1,2,3,4 (attenuated).
- Immunogenicity (non-inferiority between simplified formulation vs. conventional formulation) [ Time Frame: 4 weeks post vaccination ]The geometric mean of titers of neutralizing antibodies for each serotype at Week 4 postvaccination in a subgroup of adult participants without previous prior exposure to dengue and vaccinated with the conventional formulation and the simplified formulation of the dengue 1, 2, 3, 4 (attenuated) vaccine.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||24 Months to 59 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Children who have completed 24 months of age, adolescents and adults who have not completed 60 years of age;
- Agree with periodic contacts, either/or by phone, electronic means, and home visits.
- Show voluntary intention to participate in the study, documented by the participant's or participant's legal representative's signature of the informed consent form.
- For women: Pregnancy (confirmed by positive beta-hCG test) or breastfeeding;
- Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as per clinical history and/or physical examination;
- Compromised immune system diseases including: decompensated diabetes mellitus, cancer (except basal cell carcinoma), congenital or acquired immune deficiencies and not controlled autoimmune, as per clinical history and/or physical examination;
- Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements;
- Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history;
- History of severe allergic reactions or anaphylaxis to the vaccine or to components of the vaccine in study;
- History of asplenia;
- Use of any investigational product within 28 days before or after receiving this study vaccination;
- Has participated in another clinical trial six months prior to inclusion in the study or planning to participate in another clinical trial within 2 years following inclusion;
- Use of immunosuppressant drugs such as: antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, and corticosteroids use (except topical or nasal). For this protocol will be considered for exclusion use of corticosteroids 3 months prior to the inclusion in the study and 6 months prior to the inclusion for the other therapies mentioned, and planned use of any immunosuppressant therapy within 2 years following inclusion in the study. It will be considered immunosuppressive dose of corticosteroids the equivalent to a dose ≥20 mg of prednisone per day for adults and the equivalent of prednisone at 2 mg/kg/day for children for over 7 days;
- Have received blood products in the past three months, including transfusions or immunoglobulin, or scheduled administration of blood products or immunoglobulin for the following 2 years after vaccination;
- Fever or suspected fever within 72 hours prior to vaccination or axillary temperature greater than 37,8°C on the day of vaccination (inclusion might be postponed until participant has completed 72 hours of no fever);
- Have received live virus vaccine within 28 days or killed virus vaccine in the last 14 days prior to vaccination, or have a scheduled immunization during the first 28 days after receiving the investigational product;
- Any other condition that might put in risk the safety/rights of a potential participant or hurdle his/her compliance with this protocol in investigator's opinion or his representative physician.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02406729
|Study Director:||Fernanda C Boulos, MD, PhD||Instituto Butantan|
|Responsible Party:||Butantan Institute|
|Other Study ID Numbers:||
U1111-1168-8679 ( Registry Identifier: UTN )
|First Posted:||April 2, 2015 Key Record Dates|
|Last Update Posted:||January 18, 2023|
|Last Verified:||January 2023|
Vector Borne Diseases
RNA Virus Infections
Hemorrhagic Fevers, Viral